Skip to main content

Advertisement

Log in

Successful treatment of postsurgical hypoparathyroidism by intramuscular injection of vitamin D3 in a patient associated with malabsorption syndrome due to multiple abdominal surgeries

  • Case Report
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

A 56-year-old patient with postsurgical hypothyroidism and hypoparathyroidism associated with gastrointestinal malabsorption syndrome was prescribed with l-thyroxine and 1α(OH)D3 at a massive daily dosage of 600 and 39 μg, respectively. Although the patient became nearly euthyroid, she had been hypocalcemic, requiring frequent intravenous injection of calcium gluconate to prevent tetany. Because the serum level of 1,25(OH)2D hardly increased after an oral intake of 21 μg 1α(OH)D3, vitamin D3 was administered intramuscularly. After stoss therapy (600,000 IU), the patient has been receiving 300,000 IU vitamin D3 at intervals of 2–4 months so that she remained slightly hypocalcemic (7–8 mg/dl). At 1.5 years later, serum levels of 25(OH)D and 1,25(OH)2D were maintained at about 60 ng/ml and 30–50 pg/ml, respectively, and renal function was maintained well. These data suggest that intramuscular injection of 300,000 IU vitamin D3 at an interval of a few months to maintain a slightly increased serum level of 25(OH)D and a slightly decreased serum level of calcium is a safe and cost-effective treatment in such a parathyroid hormone-deficient hypoparathyroid patient with malabsorption syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Goltzman D, Code DEC (2003) Hypoparathyroidism. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th edn. The American Society for Bone and Mineral Research. Raven Press, New York, pp 274–278

    Google Scholar 

  2. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281

    Article  CAS  PubMed  Google Scholar 

  3. Okano K, Furukawa Y, Morii H, Fujita T (1982) Comparative efficacy of various vitamin D metabolites in the treatment of various types of hypoparathyroidism. J Clin Endocrinol Metab 55:238–243

    Article  CAS  PubMed  Google Scholar 

  4. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF (1995) Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 273:808–812

    Article  CAS  PubMed  Google Scholar 

  5. Smallridge RC, Burman KD, Wartofsky L (1990) Malabsorption of thyroxine, calcium, and vitamin D in a thyroparathyroidectomized woman: efficacy of therapy with medium-chain triglyceride oil. Mil Med 155:156–158

    CAS  PubMed  Google Scholar 

  6. Armas LAG, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89:5387–5391

    Article  CAS  PubMed  Google Scholar 

  7. Kayne LH, Lee DB (1993) Intestinal magnesium absorption. Miner Electrolyte Metab 19:210–217

    CAS  PubMed  Google Scholar 

  8. Hylander E, Madsen S (1979) 1α-Hydroxyvitamin D3 treatment of therapy-resistant symptomatic hypocalcemia in a hypoparathyroid patient with intestinal malabsorption. Acta Med Scand 205:603–605

    CAS  PubMed  Google Scholar 

  9. Didden P, Penning C, Masclee AA (2006) Octreotide therapy in dumping syndrome: analysis of long-term results. Aliment Pharmacol Ther 24:1367–1375

    Article  CAS  PubMed  Google Scholar 

  10. Drug package insert for 1α-OHD3 (Standard commodity classification number of Japan; #873112), November 2007. Teijin Pharma, Ltd, Tokyo, Japan

  11. Yamamoto M, Akatsu T, Nagase T, Ogata E (2000) Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? J Clin Endocrinol Metab 85:4583–4591

    Article  CAS  PubMed  Google Scholar 

  12. Diamond TH, Ho KW, Rohl PG, Meerkin M (2005) Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust 183:10–12

    PubMed  Google Scholar 

  13. Bringhurst FR, Demay MB, Kronenburg HM (2003) Hormones and disorders of mineral metabolism. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky MD (eds) Williams textbook of endocrinology, 10th edn. Saunders, Philadelphia, pp 1303–1371

    Google Scholar 

  14. Davies M, Berry JL, Mee AP (2005) Bone disorders associated with gastrointestinal and hepatobiliary disease. In: Feldman D, Pike JW, Glorieuz FH (eds) Vitamin D, 2nd edn. Elsevier Academic Press, New York, pp 1293–1311

    Google Scholar 

  15. Vieth R (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 9:842–856

    Google Scholar 

  16. Heikinheimo RJ, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela RH, Kataja JM, Kokko AM, Kolho LA, Rajala SA (1992) Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 51:105–110

    Article  CAS  PubMed  Google Scholar 

  17. Burns J, Paterson CR (1985) Single dose vitamin D treatment for osteomalacia in the elderly. Br Med J (Clin Res Ed) 290:281–282

    Article  CAS  Google Scholar 

  18. Omdahl J, May B (2005) The 25-hydroxyvitamin D-24-hydroxylase. In: Feldman D, Pike JW, Glorieuz FH (eds) Vitamin D, 2nd edn. Elsevier Academic Press, New York, pp 1293–1311

    Google Scholar 

  19. Nakajima K, Nohtomi K, Sato M, Takano K, Sato K (2009) PTH(7-84) inhibits PTH(1-34)-induced production of 1,25-(OH)2D3 in primary cultured murine renal tubules. Biochem Biophys Res Commun 27:224–233

    CAS  Google Scholar 

  20. Sato K, Emoto N, Toraya S, Tsushima T, Demura H, Tsuji N, Inaba S, Takeuchi A, Kobayashi T (1994) Progressively increased serum 1,25-dihydroxyvitamin D2 concentration in a hypoparathyroid patient with protracted hypercalcemia due to vitamin D2 intoxication. Endocr J 41:329–337

    Article  CAS  PubMed  Google Scholar 

  21. Toskes PP (1995) Bacterial overgrowth syndromes. In: Haubrich W, Schaffer F, Berk JE (eds) Boccus gastroenterology, vol 2, 5th edn. W.B. Saunders, Philadelphia, pp 1174–1182

    Google Scholar 

  22. Bikle DD (2007) Vitamin D insufficiency/deficiency in gastrointestinal disorders. J Bone Miner Res 22:S50–S54

    Article  Google Scholar 

  23. Lauritano EC, Bilotta AL, Gabrielli M, Scarpellini E, Lupascu A, Laginestra A, Novi M, Sottili S, Serricchio M, Cammarota G, Gasbarrini G, Pontecorvi A, Gasbarrini A (2007) Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab 92:4180–4184

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was partly supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (no. 20591102).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kanji Sato.

About this article

Cite this article

Seki, T., Yamamoto, M., Ohwada, R. et al. Successful treatment of postsurgical hypoparathyroidism by intramuscular injection of vitamin D3 in a patient associated with malabsorption syndrome due to multiple abdominal surgeries. J Bone Miner Metab 28, 227–232 (2010). https://doi.org/10.1007/s00774-009-0114-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-009-0114-2

Keywords

Navigation